Myeloproliferative Neoplasms

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

An agreement has been reached to submit a new drug application for the potential accelerated approval of the JAK2/FLT3 inhibitor pacritinib for use in patients with myelofibrosis and severe thrombocytopenia.

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.

The myelofibrosis paradigm is bursting with novel agents and combinations that have been developed with the ultimate goal of helping patients live longer.

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

The presence of RAS/CBL mutations was found to be associated with adverse phenotypic features and survival outcomes in patients with myelofibrosis.

Emerging evidence suggests that clinical variables should not be the only consideration in prognostic and risk stratification scoring systems; genomically informed tools carry equal, if not refined, insights regarding patient outcomes.

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Omar Alkharabsheh, MD, discusses novel agents under exploration in the field of myelofibrosis.

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

Jerry L​e Pow Spivak, MD, discusses the prevalence of polycythemia vera.  

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Omar Alkharabsheh, MD, discusses the growing treatment options for patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, and how available agents have not induced a biological change or shown improvement in disease outcomes.

Omar Alkharabsheh, MD, discusses the current goals of treatment in myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

The presence of MPL mutations in patients with essential thrombocythemia was found to be associated with an increased risk of myelofibrotic transformation.

Intravenous rigosertib did not meet the primary end point of significantly improved overall survival versus physician’s choice of therapy plus best supportive care in patients with higher-risk myelodysplastic syndromes.

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials. 

Patients with myelodysplastic syndromes who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations.

Pretreatment with the investigational JAK2/FLT3 inhibitor pacritinib prior to allogeneic stem cell transplant was shown to be feasible and safe in patients with primary, post-polycythemia vera or post-essential thrombocythemia myelofibrosis.

Patients with a suspected or diagnosed myeloproliferative neoplasm should undergo targeted next-generation sequencing versus sequential or allele specific testing to reduce the risk of identifying a false driver mutation or an excluded diagnosis of MPN.